The estimated Net Worth of Luciano Adorini is at least $281 Tausend dollars as of 6 July 2015. Luciano Adorini owns over 4,067 units of Intercept Pharmaceuticals Inc stock worth over $280,744 and over the last 12 years Luciano sold ICPT stock worth over $0.
Luciano has made over 16 trades of the Intercept Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Luciano exercised 4,067 units of ICPT stock worth $86,586 on 6 July 2015.
The largest trade Luciano's ever made was exercising 11,038 units of Intercept Pharmaceuticals Inc stock on 12 August 2014 worth over $95,699. On average, Luciano trades about 1,572 units every 24 days since 2012. As of 6 July 2015 Luciano still owns at least 14,776 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Luciano Adorini stock trades at the bottom of the page.
Luciano's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK, NY, 10013.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein und Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: